STOCK TITAN
  1. Home
  2. Sec-filings
  3. KYTX
  4. [Form 4] Kyverna Therapeutics, Inc. Insider Trading Activity

Kyverna Therapeutics (KYTX) director granted RSUs and options vesting in 2027

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kyverna Therapeutics director Ian T. Clark received new equity awards. He was granted 5,093 restricted stock units of common stock, bringing his direct common share holdings to 21,727. He also received options for 20,582 shares at an exercise price of $8.59, expiring in 2036.

Both the RSUs and options will fully vest on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual stockholders’ meeting, as long as he remains in continuous service through that date.

Positive

  • None.

Negative

  • None.
Insider CLARK IAN T
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 20,582 $0.00 --
Grant/Award Common Stock 5,093 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 20,582 shares (Direct, null); Common Stock — 21,727 shares (Direct, null)
Footnotes (1)
  1. Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
RSU grant 5,093 shares Restricted stock unit award of common stock
Common shares after grant 21,727 shares Direct common stock holdings after RSU award
Option grant size 20,582 shares Stock Option (right to buy) underlying common shares
Option exercise price $8.59 per share Conversion or exercise price for stock option grant
Option expiration 2036-05-27 Expiration date of the stock option grant
restricted stock unit financial
"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (right to buy) financial
"Stock Option (right to buy) with underlying security title Common Stock and 20,582.0000 shares"
vest financial
"which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of stockholders financial
"immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CLARK IAN T
(Last)(First)(Middle)
C/O KYVERNA THERAPEUTICS, INC.
5980 HORTON ST., STE 200
(Street)
EMERYVILLE CALIFORNIA 94608
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/27/2026A5,093(1)A$021,727D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$8.5905/27/2026A20,582 (2)05/27/2036Common Stock20,582$020,582D
Explanation of Responses:
1. Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
2. All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
By: /s/ Samantha H. Eldredge, as Attorney-in-fact05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Kyverna Therapeutics (KYTX) report for Ian T. Clark?

Kyverna Therapeutics reported that director Ian T. Clark received equity compensation, including restricted stock units and stock options. These awards increase his direct ownership stake and align his interests with shareholders through time-based vesting tied to his continued service on the board.

How many Kyverna Therapeutics (KYTX) shares did Ian T. Clark receive in RSUs?

Ian T. Clark received 5,093 restricted stock units of Kyverna Therapeutics common stock. These RSUs will vest in full on a future date if he continues serving, turning into an equivalent number of shares once vested and settled according to the company’s equity award terms.

What are the details of Ian T. Clark’s Kyverna Therapeutics (KYTX) stock option grant?

Clark received stock options covering 20,582 Kyverna common shares at an exercise price of $8.59 per share. All option shares will become fully vested and exercisable in 2027, provided he maintains continuous service, and the options are scheduled to expire in 2036 if not exercised earlier.

When do Ian T. Clark’s new Kyverna Therapeutics (KYTX) equity awards vest?

Both the restricted stock units and the stock options will fully vest on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual stockholders’ meeting. Vesting depends on Clark’s continuous service with the company through the applicable vesting date, without interruption.

What is Ian T. Clark’s Kyverna Therapeutics (KYTX) shareholding after this Form 4?

After the RSU grant, Clark directly holds 21,727 Kyverna common shares. He also holds options for 20,582 additional shares that are not yet exercisable. This reflects his updated equity position as a company director following the reported compensation awards on the transaction date.